Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$2000

The Mild Cognitive Impairment pipeline market report provides a comprehensive overview of the therapeutics under development for Mild Cognitive Impairment, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for Mild Cognitive Impairment and features dormant and discontinued projects.

Mild Cognitive Impairment Pipeline Drugs Market by Key Targets

In the Mild Cognitive Impairment pipeline drugs market, the key targets are Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor.

Key Targets in the Mild Cognitive Impairment Pipeline Drugs Market

Key Targets in the Mild Cognitive Impairment Pipeline Drugs Market

For more target insights, download a free report sample

Key MoA in the Mild Cognitive Impairment Pipeline Drugs Market

Some of the key mechanisms of action in the Mild Cognitive Impairment pipeline drugs market are Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor.

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by MoA

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by MoA

To get more insights on key MoA, download a free sample report

Mild Cognitive Impairment Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the Mild Cognitive Impairment pipeline drug market are oral, intravenous, subcutaneous, inhalational, nasal, buccal, intraarticular, and sublingual. Oral has the maximum number of pipeline products.

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by RoA

Mild Cognitive Impairment Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the Mild Cognitive Impairment Pipeline Drugs Market

The key molecule types in the Mild Cognitive Impairment pipeline drugs market are Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, And Subunit Vaccine. Small molecule has the maximum number of pipeline products.

Mild Cognitive Impairment Pipeline Drugs Market, by Molecule Types

Mild Cognitive Impairment Pipeline Drugs Market, by Molecule Types

To get more insights on key molecule types, download a free sample report

Major Companies in the Mild Cognitive Impairment Pipeline Drugs Market

Some of the major companies in the Mild Cognitive Impairment pipeline drugs market are CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc.

Mild Cognitive Impairment Pipeline Drugs Market, by Major Companies

Mild Cognitive Impairment Pipeline Drugs Market, by Major Companies

For more company insights, download a free sample report

Mild Cognitive Impairment Pipeline Drugs Market Overview

Key Targets Amyloid Beta A4 Protein, Beta 2 Adrenergic Receptor, Glutamate Ionotropic Receptor NMDA Type Subunit, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Glucagon Like Peptide 1 Receptor, Microtubule Associated Protein Tau, Acetylcholinesterase, Bcr-Abl Tyrosine Kinase, and Brain Derived Neurotrophic Factor
Key Mechanisms of Action Amyloid Beta A4 Protein Inhibitor, Beta 2 Adrenergic Receptor Agonist, Glutamate Ionotropic Receptor NMDA Type Subunit Agonist, Beta 2 Adrenergic Receptor Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Glucagon Like Peptide 1 Receptor Agonist, Microtubule Associated Protein Tau Inhibitor, Acetylcholinesterase Inhibitor, and Bcr-Abl Tyrosine Kinase Inhibitor
Key Routes of Administration Oral, Intravenous, Subcutaneous, Inhalational, Nasal, Buccal, Intraarticular, and Sublingual
Key Molecule Types Small Molecule, Monoclonal Antibody, Synthetic Peptide, Peptide, Antibody, Cell Therapy, Gene Therapy, Recombinant Protein, and Subunit Vaccine
Major Companies CuraSen Therapeutics Inc, AgeneBio Inc, Merck & Co Inc, Actinogen Medical Ltd, Acumen Pharmaceuticals Inc, Addex Therapeutics Ltd, Aptinyx Inc, Araclon Biotech SL, AstraZeneca Plc, and Biomed Industries Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Mild Cognitive Impairment
  • The pipeline guide reviews pipeline therapeutics for Mild Cognitive Impairment by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Mild Cognitive Impairment therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Mild Cognitive Impairment therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for Mild Cognitive Impairment

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Mild Cognitive Impairment
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Mild Cognitive Impairment pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Actinogen Medical Ltd
Acumen Pharmaceuticals Inc
Addex Therapeutics Ltd
AgeneBio Inc
Aptinyx Inc
Araclon Biotech SL
AstraZeneca Plc
Biomed Industries Inc
CereSpir Inc
CuraSen Therapeutics Inc
Eisai Co Ltd
Eli Lilly and Co
FUJIFILM Toyama Chemical Co Ltd
Gray Matter
Grespo AB
ImmunoChem Therapeutics LLC
IntelGenx Corp
INVENT Pharmaceuticals Inc
Jupiter Neurosciences Inc
KeifeRx LLC
Merck & Co Inc
NeurAegis Inc
Neuraly Inc
NKGen Biotech Inc
NLS Pharmaceutics AG
Novartis AG
Novo Nordisk AS
Octapharma AG
Partner Therapeutics Inc
Pfizer Inc
ProNeurogen Inc
Sage Therapeutics Inc
SBI Pharmaceuticals Co Ltd
SciSparc Ltd
Shackelford Pharma Inc
TauRx Therapeutics Ltd
UCB SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mild Cognitive Impairment – Overview

Mild Cognitive Impairment – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Mild Cognitive Impairment – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mild Cognitive Impairment – Companies Involved in Therapeutics Development

Mild Cognitive Impairment – Drug Profiles

Mild Cognitive Impairment – Dormant Projects

Mild Cognitive Impairment – Discontinued Products

Mild Cognitive Impairment – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Mild Cognitive Impairment, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Mild Cognitive Impairment – Dormant Projects, 2022

Mild Cognitive Impairment – Dormant Projects, 2022 (Contd..1)

Mild Cognitive Impairment – Dormant Projects, 2022 (Contd..2)

Mild Cognitive Impairment – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Mild Cognitive Impairment, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,000

Can be used by individual purchaser only

$6,000

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Mild Cognitive Impairment Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.